FrancophonIA/ELRC3.0 huggingface dataset:
English: These include: anti-bacterial medicines (gentamycin, tobramycin, ciprofloxacin), anti-fungal medicines which contain amphotericin B, medicines used for urinary tract infections which contain trimethoprim, medicines for cancer which contain melphalan, medicines used to lower the amount of acid in your stomach (acid secretion inhibitors of the H2-receptor antagonist type), tacrolimus, pain killers (non-steroid antiinflammatory medicines such as diclofenac), fibric acid medicines (used to lower the amount of fat in the blood).
Maltese: Dawn jinkludu: mediċini antibatteriċi (gentamycin, tobramycin, ciprofloxacin), mediċini antifungali li fihom amphotericin B, mediċini użati biex jikkuraw infezzjonijiet fil-passaġġ tal-awrina li fihom trimethoprim, mediċini għall-kanċer li fihom melphalan, mediċini użati biex ibaxxu l-ammont ta' aċdu flistonku tiegħek (inibituri tal-ħruġ tal-aċdu tar-riċettur H2 tat-tip antagonist), tacrolimu, pilloli li jrażżnu l-uġigħ (mediċini antiinfjammatorji mhux sterojdi bħal diclofenac), mediċini tal-aċidi fibriċi (użati biex jitbaxxa l-ammont ta' xaħam fid-demm).
English: If any of these drugs are used concurrently with ciclosporin, close clinical observation is required in order to enable early detection of toxic manifestations of the medicinal products, followed by reduction of its dosage or its withdrawal.
Maltese: Jekk kwalunkwe waħda minn dawn il-mediċini tintuża flimkien ma' ciclosporin, osservazzjoni klinika mill-qrib tkun meħtieġa sabiex wieħed ikun jista' jinnota manifestazzjonijiet tossiċi bikrija tal-prodotti mediċinali, u wara jkun hemm tnaqqis tad-doża mogħtija jew titwaqqaf.
English: Hyperlipidaemia
Maltese: Popolazzjoni pedjatrika
English: Pharmacokinetic data from paediatric patients given Sandimmun Neoral or Sandimmun are very limited.
Maltese: Teżisti esperjenza limitata b'Sandimmun f'pazjenti anzjani.
English: Some examples are listed below:
Maltese: Kellem lit-tabib tiegħek qabel ma tieħu Sandimmun:
English: Intravenous use
Maltese: Dożi disponibbli
English: There is only limited experience with the use of Sandimmun in children with endogenous uveitis.
Maltese: Teżisti biss esperjenza limitata bl-użu ta' Sandimmun fi tfal b'endogenous uveitis.
English: To achieve initial remission, or to counteract inflammatory ocular attacks, systemic corticosteroid treatment with daily doses of 0.2 to 0.6 mg/kg prednisone or an equivalent may be added if Sandimmun alone does not control the situation sufficiently.
Maltese: Sabiex tinkiseb ir-remissjoni inizjali, jew sabiex jingħelbu l-attakki okulari infjammatorji, jista' jiżdied trattament sistemiku bil-kortikosterojdi b'dożi ta' bejn 0.2 u 0.6 mg/kg prendnisone kuljum jew ekwivalenti jekk Sandimmun waħdu ma jikkontrollax is-sitwazzjoni b'mod effiċjenti.
English: Skin infections with Staphylococcus aureus are not an absolute contraindication for Sandimmun therapy, but should be controlled with appropriate antibacterial agents.
Maltese: Infezzjonijiet fil-ġilda b'Staphylococcus aureus mhumiex kontraindikazzjoni assoluta għal terapija b'Sandimmun, imma għandhom ikunu kkontrollati b'aġenti antibatteriċi xierqa.
English: If the renal function (except for proteinuria) is normal, the recommended daily dose is the following: - adults: 5 mg/kg - children: 6 mg/kg
Maltese: -adulti: 5 mg/kg -tfal: 6 mg/kg
English: A significantly increased exposure to anthracycline antibiotics (e.g. doxorubicine, mitoxanthrone, daunorubicine) was observed in oncology patients with the intravenous co-administration of anthracycline antibiotics and very high doses of ciclosporin.
Maltese: Kien hemm żieda qawwija fl-espożizzjoni għall-antibjotiċi anthracycline (eż. doxorubicine, mitoxanthrone, daunorubicine) f'pazjenti tal-onkoloġija bl-għoti flimkien ta' antibjotiċi anthracycline fil-vini u ta' dożi qawwija ħafna ta' ciclosporin.
English: Concomitant use of ciclosporin and tacrolimus should be avoided (see section 4.5).
Maltese: L-użu flimkien ta' ciclosporin u tacrolimus għandu jkun evitat (ara sezzjoni 4.5).
English: Caution is also required when ciclosporin is co-administered with potassium-sparing drugs (e.g. potassiumsparing diuretics, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists) or potassium-containing medicinal products as well as in patients on a potassium rich diet. Control of potassium levels in these situations is advisable.
Maltese: Wieħed jeħtieġ joqgħod attent meta ciclosporin jingħata flimkien ma' mediċini b'potassju meqjus (eż. dijuretiċi b'potassju meqjus, inibituri tal-enzima li tikkonverti l-anġjotensini (ACE), antagonisti tarriċetturi tal-anġjotensin II) jew prodotti mediċinali li fihom il-potassju, kif ukoll f'pazjenti b'dieta rikka fil-potassju.
English: Do not use Sandimmun: - if you are allergic to ciclosporin or any of the other ingredients of this medicine (listed in section 6; also see section “Sandimmun contains castor oil and ethanol”).
Maltese: Tużax Sandimmun: jekk int allerġiku għal ciclosporin jew għal xi sustanza oħra ta' din il-mediċina (elenkati fissezzjoni 6; ara wkoll is-sezzjoni taħt “Sandimmun fih castor oil u ethanol”).
English: The total dose each day is usually between 3 mg per kilogram of your body weight and 5 mg per kilogram body weight.
Maltese: Artrite rewkatojde gravi - Id-doża totali għal kuljum hi normalment ta' bejn 3 mg għal kull kilo tal-piż tiegħek u 5 mg għal kull kilo tal-piż tiegħek.
English: Hepatotoxicity and liver injury including cholestasis, jaundice, hepatitis and liver failure with some fatal outcome (see section 4.4) Skin and subcutaneous tissue disorders Very common
Maltese: Epatotossiċità u ħsara fil-fwied inkluż kolestażi, suffejra, epatite u disfunzjoni tal-fwied b'xi riżultati fatali (ara sezzjoni 4.4)
English: Renal dysfunction (see section 4.4) Reproductive system and breast disorders Rare
Maltese: Disturbi fil-kliewi u fis-sistema urinarja Komuni ħafna Disfunzjoni renali (ara sezzjoni 4.4).
English: Drugs that decrease ciclosporin levels
Maltese: Mediċini li jżidu l-livelli ta' ciclosporin
English: Effects of ciclosporin on other drugs
Maltese: Effetti ta' ciclosporin fuq mediċini oħrajn
English: Each mark on the syringe is 0.1 ml.
Maltese: 0.1 ml.
English: 50 ml amber glass bottles with an aluminium cap and rubber stopper.
Maltese: 50 ml fliexken tal-ħġieġ ta' lewn l-ambra b'tapp tal-aluminju u b'ieħor tal-lastiku.
English: Sandimmun and associated names (see Annex I) 25 mg soft capsules Sandimmun and associated names (see Annex I) 50 mg soft capsules Sandimmun and associated names (see Annex I) 100 mg soft capsules [See Annex I - To be completed nationally]
Maltese: Sandimmun u ismijiet assoċjati (ara Annex I) 50 mg/ml konċentrazzjoni għal soluzzjoni għallinfużjoni [Ara Anness I - Biex timtela mill-pajjiż partikolari]
English: Lymphadenopathy observed on treatment with ciclosporin should be regularly monitored.
Maltese: Jekk hemm limfadenopatija waqt it-trattament b'ciclosprin din għandha tkun immonitorata b'mod regolari.
English: Statin therapy needs to be temporarily withheld or discontinued in patients with signs and symptoms of myopathy or those with risk factors predisposing to severe renal injury, including renal failure, secondary to rhabdomyolysis.
Maltese: Ikun meħtieġ li titwaqqaf momentarjament jew għal kollox it-terapija b'statin f'pazjenti b'sinjali u sintomi ta' mijopatija jew dawk b'fatturi riskjużi li jippredisponu ħsara gravi lill-kliewi, inkluż kollass renali, u aktar gravi rabdomijolisi.
English: Hepatobiliary disorders Common
Maltese: Antibjotiċi macrolide:
English: NAME OF THE MEDICINAL PRODUCT Sandimmun and associated names (see Annex I) 100 mg/ml oral solution [See Annex I - To be completed nationally]
Maltese: Sandimmun u ismijiet assoċjati (ara Anness I) 100 mg/ml soluzzjoni orali [Ara Anness I - Biex timtela mill-pajjiż partikolari]
English: Such diseases include eye problems which threaten your vision (endogenous uveitis, including Behçet's uveitis), severe cases of certain skin diseases (atopic dermatitis, or eczema and psoriasis), severe rheumatoid arthritis and a kidney disease called nephrotic syndrome.
Maltese: Dawn il-mardiet jinkludu problemi tal-għajn li jheddu l-vista (endogenous uveitis, inkluż uveitis ta' Behçet), każijiet gravi ta' ċerti mardiet tal-ġilda (dermatite atopika, jew ekżema, u psorajsi), artrite rewmatojde gravi u mard tal-kliewi msejjaħ sindrome nefrotika.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml oral solution contains 100 mg ciclosporin.
Maltese: • Is-sustanza attiva hi ciclosporin. ml 1 ta' soluzzjoni orali fiha 100 mg ciklosporin.
English: Special excipients: Ethanol
Maltese: Sandimmun fih l-ethanol.
English: • Fits (seizures).
Maltese: • il-lipidi fid-demm (xaħmijiet) tiegħek.
English: The full EPAR for Roteas can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The usual dose is 60 mg once a day.
Maltese: -doża normali hija 60 mg darba kuljum.
English: Roteas edoxaban
Maltese: -użu ta
English: Other information about Roteas
Maltese: Informazzjoni oħra dwar Roteas
English: Why is Roteas approved?
Maltese: Għaliex ġie approvat Roteas?
English: Roteas is available as tablets (15, 30 and 60 mg) and can only be obtained with a prescription.
Maltese: 'pilloli ta' (15, 30 u 60
English: This means that it blocks factor Xa, an enzyme that is involved in the production of thrombin.
Maltese: Dan ifisser li din timblokka lfattur Xa, enzima involuta fil-produzzjoni tat-trombina.
English: Roteas contains the active substance edoxaban.
Maltese: Roteas fih is-sustanza attiva edoksaban.
English: Further episodes were seen in 130 of 4,118 patients given edoxaban (3.2%) and in 146 of 4,122 given warfarin (3.5%).
Maltese: '146 minn 4,122 li ngħataw warfarin (3.5% ).
English: When another recommended definition of the type of stroke was used, embolism or stroke due to blood clots was seen in 143 patients given Roteas (0.9%) and 157 given warfarin (1%).
Maltese: ' puplesija, ġie emboliżmu jew puplesija minħabba emboli tad-demm f pazjent li ngħataw Roteas (0.9%) u 157 li ngħataw warfarin (1%).
English: Roteas is an anticoagulant medicine (a medicine that prevents blood clotting) used in adults:
Maltese: Roteas huwa mediċina antikoagulanti (mediċina li tipprevjeni l-għaqid tad-demm) li jintuża fl-adulti:
English: • to treat deep-vein thrombosis (DVT, a blood clot in a deep vein, usually in the leg) and pulmonary embolism (a clot in a blood vessel supplying the lungs), and to prevent DVT and pulmonary embolism from re-occurring.
Maltese: • biex jikkura trombożi fil-vini fondi (DVT, embolu tad-demm ġo vina fonda, ġeneralment fir-riġel) u emboliżmu pulmonari (embolu fil-vina li tissupplixxi lill-pulmuni), u biex jipprevjeni milli d-DVT u lemboliżmu pulmonari jerġgħu jseħħu.
English: Roteas has been shown to be as effective as the standard anticoagulant warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation.
Maltese: Roteas intwera li huwa effikaċi daqs l-antikoagulant standard warfarin biex jipprevjeni puplesija u emboliżmu sistemiku f
English: In the treatment and prevention of blood clots in patients with DVT or pulmonary embolism, Roteas was also found to be as effective as warfarin, in a study involving over 8,200 patients.
Maltese: 'pazjenti b' DVT j instab ukoll li huwa effikaċi daqs warfarin, fi studju li involva aktar minn 8,200 pazjent.
English: The effects were studied in one main study, which involved over 21,000 patients for an average of 2.5 years.
Maltese: -effetti ġew studjati fi studju wieħed ewlieni, li involva aktar minn 21,000 pazjent għal medja ta' sentejn u nofs.
English: By blocking factor Xa, the medicine reduces the levels of thrombin in the blood, which helps treat clots and reduce the risk of them forming in the arteries and veins and leading to DVT, pulmonary embolism, stroke or other organ damage.
Maltese: 'hekk tgħin biex tikkura l-emboli u tnaqqas ir-riskju li dawn jiffurmaw fl-arterji u fil-vini u twassal għal DVT, emboliżmu pulmonari, puplesija jew ħsara oħra fl-organi.
English: EPAR summary for the public
Maltese: Sommarju tal-EPAR għall-pubbliku edoksaban
English: This medicine is the same as Lixiana, which is already authorised in the European Union (EU).
Maltese: Din il-mediċina hija l-istess bħal Lixiana, li diġà hija awtorizzata fl-Unjoni Ewropea (UE).
English: This is a summary of the European public assessment report (EPAR) for Roteas.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta
English: What are the risks associated with Roteas?
Maltese: -riskji asso ċjati ma' Roteas?
English: There was a trend for better results in patients with reduced kidney function than those whose kidney function was normal.
Maltese: -funzjoni tal-kliewi minn dawk li l-funzjoni tal-kliewi tagħhom kienet normali.
English: A first systemic embolism or stroke occurred in 182 patients given standard doses of Roteas and in 232 of those given warfarin, corresponding to annual rates for these events of around 1.2% and 1.5% respectively.
Maltese: L-ewwel emboliżmu sistemiku jew puplesija se ħħew f pazjent li ng ħataw dożi standard t ngħataw warfarin, li jikkorrispondu għal rati annwali għal dawn l-avvenimenti ta r 1.2% u
English: • to prevent stroke (caused by blood clots in the brain) and systemic embolism (blood clots in other organs) in patients with non-valvular atrial fibrillation (irregular rapid contractions of the upper chambers of the heart).
Maltese: • biex jipprevjeni puplesija (ikkawżata minn emboli tad-demm fil-moħħ) u emboliżmu sistemiku
English: The most common side effects with Roteas (which may affect up to 1 in 10 people) are bleeding from skin and soft tissues, nose (epistaxis) and the vagina.
Maltese: 'Roteas (li jistgħu fsada mill-ġilda u mit-tessuti rotob, mill-imnieħer (epistassi) u mill-vaġina.
English: It will also carry out a study of the effects of the medicine in patients with atrial fibrillation and good kidney function.
Maltese: 'fibrillazzjoni atrijali u fil
English: Other common side effects are anaemia (low levels of red blood cells), rash and abnormal results in tests of liver function.
Maltese: -demm), raxx u riżultati anomali fit-testijiet tal-funzjoni talfwied.
English: The active substance in Roteas, edoxaban, is a ‘factor Xa inhibitor'.
Maltese: -edoksaban, hija "inibitur tal-fattur Xa".
English: It is used in patients who have one or more risk factors, such as having had a previous stroke, high blood pressure, diabetes, heart failure or being 75 years old or over;
Maltese: 'pazjenti li ħandhom fattur ta jew aktar, bħal dawk li diġà kellhom puplesija, pressjoni tad' riskju wieħed demm għolja, dijabete, insuffiċjenza kardijaka jew dawk li għandhom 75 sena jew aktar;
English: Titanium dioxide (E171)Red iron oxide (E172) Yellow iron oxide (E172) Talc
Maltese: Polyvinyl alcohol Titanium dioxide (E171) Red iron oxide (E172) Yellow iron oxide (E172) Talc
English: 4.0%; CI: -22.5 to 11.7 [p=0.639]).
Maltese: (RRR =4.0 %; CI: minn -22.5 sa 11.7 [p=0.639]).
English: Date of first authorisation: 21 September 2009 Date of latest renewal: 3 June 2014
Maltese: Data tal-ewwel awtorizzazzjoni: 21 ta' Settembru 2009 Data tal-aħħar tiġdid: 03 Ġunju 2014
English: KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany
Maltese: KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Is-Slovenja TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Il-Ġermanja
English: New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively.
Maltese: Każijiet kardjovaskulari ġodda (punt aħħari ta' riferiment primarju) kienu evitati, bi tnaqqis fir-riskju relattiv ta' 22 % (CI: 8.6, 33.4), 32 % (CI: 12.8, 46.4), 4 % (CI: -26.9, 26.7), 6 % (CI: -33.5, 34.3) u 14 % (CI: -31.6, 44.2), waqt l-intervalli ta' studju ta' 0-1, 1-3, 3-6, 6-9 u 9-12 xhur, rispettivament.
English: In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy.
Maltese: F'CURE, 823 (6.6 %) pazjent ingħataw terapija ta' antagonista għar-riċettatur GPIIb/IIIa flistess ħin.
English: and acetylsalicylic acid for this condition.
Maltese: Acetylsalicylic acid (ASA):
English: Atrial fibrillation
Maltese: Fibrillazzjoni atrijali
English: The mean CHADS2 score was 2.0 (range 0-6).
Maltese: Il-medja tal-valur CHADS2 kien ta' 2.0 (marġni ta' 0-6).
English: The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR = 43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR = 18.2%; CI: 6.5%, 28.3%).
Maltese: L-użu ta' clopidogrel fi CURE kien assoċjat ma' tnaqqis fil-bżonn ta' terapija trombolitika (RRR = 43.3 %; CI: 24.3 %, 57.5 %) u impedituri ta' GPIIb/IIIa (RRR = 18.2 %; CI: 6.5 %, 28.3 %).
English: A total of 99.7% of patients received fibrinolytics (fibrin specific: 68.7%, non- fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins.
Maltese: B'kollox total ta' 99.7 % pazjenti rċevew fibrinolitiċi (speċifiċi għal fibrin: 68.7 %, mhux speċifiċi għal fibrin: 31.1 %), 89.5% heparin, 78.7 % imblokkaturi beta, 54.7 % impedituri ACE u 63 % statins.
English: TROPICAL-ACS (Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes)
Maltese: TROPICAL-ACS ( L-Ittestjar tas-Sensibilità għall-Inibizzjoni tal-Plejtlits fuq Trattament Kroniku kontra lPlejtlits għal Sindromi Koronarji Akuti- Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes)
English: - The other ingredients are microcrystalline cellulose, colloidal anhydrous silica, crospovidone (type A), macrogol 6000 and hydrogenated castor oil in the tablet core and polyvinyl alcohol, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172), talc and macrogol 3000 in the film-coating.
Maltese: - Is-sustanzi l-oħra fil-qalba tal-pillola huma microcrystalline cellulose, colloidal anhydrous silica, crospovidone (tip A), macrogol 6000, żejt ir-riġnu idroġenat u polyvinyl alcohol, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172), talc and macrogol 3000 fil-kisi tal-pillola.
English: The patient population included 19.7% women and 29.2% patients ≥ 65 years.
Maltese: Il-popolazzjoni ta' pazjenti kienu jinkludu 19.7 % nisa u 29.2 % pazjenti ≥ 65 years.
English: The recommended dose for ASA was 75 to 100 mg/day.
Maltese: Iddoża rrakkomandata ta'ASA kienet ta' 75 sa 100 mg/day.
English: 7 film-coated tablets 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 50 film-coated tablets 56 film-coated tablets 84 film-coated tablets 90 film-coated tablets 100 film-coated tablets
Maltese: 7 pilloli miksija b'rita 14-il pillola miksija b'rita 28 pillola miksija b'rita 30 pillola miksija b'rita 50 pillola miksija b'rita 56 pillola miksija b'rita 84 pillola miksija b'rita 90 pillola miksija b'rita 100 pillola miksija b'rita
English: Blister of OPA/Alu/PVC-Alu containing 7, 14, 28, 30, 50, 56, 84, 90 and 100 film-coated tablets in the box.
Maltese: Folji ta' OPA/AL/PVC-Al li fihom 7, 14, 28, 30, 50, 56, 84, 90 u 100 pillola miksija b'rita fil-kaxxa.
English: Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus
Maltese: Dermatite bulloża (nekroliżi tossika ta' l-epidermide, Sindromu ta' Stevens Johnson, eritema multiforme), exanthematous pustulosis akuta u ġeneralizzata (AGEP), anġjoedima, sindromu ta' sensittività eċċessiva kkawżat mill-mediċina, raxx kkawżat mill-mediċina b'eosinofilja u sintomi sistemiċi (DRESS), raxx eritematika jew bil-qoxra, urtikarja, ekżema, lichen planus
English: There have been a number of retrospective analyses, however, to evaluate this effect in patients treated with clopidogrel for whom there are genotyping results: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477), and ACTIVE-A (n=601), as well as a number of published cohort studies.
Maltese: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477), u ACTIVE-A (n=601), kif ukoll numru ta' studji ko-orti ppubblikati.
English: The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below.
Maltese: Ir-reazzjonijiet avversi klinikament rilevanti li ġew osservati fl-istudji CAPRIE, CURE, CLARITY, COMMIT u ACTIVE-A huma diskussi hawn taħt.
English: Cellulose, microcrystalline Colloidal anhydrous silica Crospovidone (type A) Macrogol 6000
Maltese: Crospovidone (tip A) Macrogol 6000
English: Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, eosinophilic pneumonia
Maltese: Emorraġija fil-passaġġ respiratorju (emoptassi, emorraġija pulmonari), bronkospażmu, pnewmonite interstizjali, pulmonite eosinofilika
English: The ACTIVE-A study (N=7,554) was a multicenter, randomized, double-blind, placebo-controlled study which compared clopidogrel 75 mg/day + ASA (N=3,772) to placebo + ASA (N=3,782).
Maltese: L-istudju ACTIVE-A (N=7,554), kien wieħed ikkontrollat bil-plaċebo, magħmul f'postijiet varji,doubleblind u randomized u li qabbel clopidogrel 75 mg/day + ASA (N=3,772) ma' plaċebo + ASA (N=3,782).
English: Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia
Maltese: Purpura tromboċitopenikatrombotika (thrombotic thrombocytopenic purpura (TTP) (ara sezzjoni 4.4), anemija aplastika, panċitopenija, agranuloċitosi, tromboċitopenija severa, emofilja A akwiżita, granuloċitopenija, anemija
English: Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, carbamazepine, and efavirenz.
Maltese: Prodotti mediċinali li huma inibituri qawwijin jew moderati ta' CYP2C19 jinkludu, per eżempju, omeprazole u esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine u efavirenz.
English: Very rare, not known*
Maltese: Rari ħafna, mhux magħruf
English: The mean age was 71 years, 41.6% of patients were ≥75 years.
Maltese: L-età medja kienet ta' 71 sena, 41.6 % tal-pazjenti kellhom ≥ 75 sena.
English: - carbamazepine a medicine to treat some forms of epilepsy, - moclobemide, medicine to treat depression, - repaglinide, medicine to treat diabetes, - paclitaxel, medicine to treat cancer, - anti-retroviral medicines (medicines to treat HIV infections).
Maltese: - moclobemide, mediċina għat-trattament tad-dipressjoni, - repaglinide, mediċina għat-trattament tad-dijabete, - paclitaxel, mediċina għat-trattament tal-kanċer, - mediċini antiretrovirali (mediċini għall-kura ta' infezzjonijiet bl-HIV).
English: The population included 27.8% women, 58.4% patients ≥ 60 years (26% ≥ 70 years) and 54.5% patients who received fibrinolytics.
Maltese: Il-popolazzjoni kienet tinkludi 27.8 % nisa, 58.4 % pazjenti ≥ 60 sena (26 % ≥ 70 sena) u 54.5 % pazjenti li rċevew fibrinolitiċi.
English: A total of 23.0% of patients received anti-arrhythmics, 52.1% beta-blockers, 54.6% ACE inhibitors, and 25.4% statins.
Maltese: Kien hemm 23.0 % tal-pazjenti li kienu qed jirċievi l-antiarritmiċi, 52.1 % l-beta-blokkanti, 54.6 % l-inibituri ACE u 25.4 % l-istatins.